We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Kodiak Sciences Inc (KOD) USD0.0001

Sell:$7.78 Buy:$7.79 Change: $0.14 (1.83%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$7.78
Buy:$7.79
Change: $0.14 (1.83%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$7.78
Buy:$7.79
Change: $0.14 (1.83%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kodiak Sciences Inc. is a biopharmaceutical company, is engaged in the research, development and commercializing transformative therapeutics to treat high prevalence retinal diseases in the United States and additional international markets. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.

Contact details

Address:
1200 PAGE MILL RD
PALO ALTO
94304
United States
Telephone:
+1 (650) 2810850
Website:
https://kodiak.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KOD
ISIN:
US50015M1099
Market cap:
$411.47 million
Shares in issue:
51.95 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Victor Perlroth
    Chairman of the Board, President, Chief Executive Officer
  • John Borgeson
    Chief Financial Officer, Senior Vice President, Secretary
  • Jason Ehrlich
    Chief Medical Officer and Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.